Mobile

12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENTS W...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-006451-39

12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENTS WITH OVERACTIVE BLADDER

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the efficacy of fesoterodine with that of placebo and of tolterodine ER in subjects with overactive bladder, after 12 weeks of treatment.

Critère d'inclusion

  • Treatment of overactive bladder with symptoms of frequency, urgency, and urgency incontinence

Liens